- Synthesized and communicated forecasting and market research insights to Executive Marketing Director and VP of Oncology to influence short-term tactical planning (e.g., HCP and patient messaging) and long-term lifecycle management decisions (e.g., go/no-go decision, trial design)- Led short-term and long-term financial forecast for a leukemia blockbuster drug, Venclexta, in both launch and line-extension indications (CLL, AML, MM, MDS); developed and managed patient-level incidence-based forecasting models in Excel and ForecastHorizon- Robust launch planning experience as the MDS and MM launch analytics lead (e.g., insights research planning, HCP segmentation and targeting, patient pain point identification) - Conducted 4 ad-hoc commercial assessments for line extension opportunities to inform clinical trial design, business development decisions - Managed 7 launch and line extensions market research projects (e.g., patient journey, TPP testing, message testing, health equity) to inform brand strategy and positioning- Led and facilitated strategic heme-franchise patient journey workstream with over 30 cross-functional stakeholders (e.g., marketing, medical, HEOR, field); influenced senior leadership to shift to patient-centric outcome planning- Strong understanding of the U.S. market access landscape with hands-on experience in developing IRA assumptions and considerations to inform lifecycle management and long-term resource planning- Experience in driving complex organization-wide oncology health equity capability, including framing key questions under ambiguity, developing analytics best practices, socialization and measurement plan, roadshow presentation, and brand team pull-through plans- Robust understanding of secondary data sources (syndicated sales, longitudinal patient-level data, IQVIA, Symphony Health) with excellent skills to translate data into actional recommendations for business growth

- Advised global biopharma and biotech clients in 13 engagements including commercial assessment, therapeutic area strategy, corporate strategy, indication prioritization, competitive landscape, due diligence, and pricing & market access- Therapeutic area experience in oncology (NSCLC, breast, bladder, HNSCC, CRC, ovarian, endometrial, AML), inflammation, cardiovascular, CNS and rare diseases; platform knowledge in cell and gene therapy, ADC, nucleic-acid therapy; significant project work in U.S. and ex-U.S. (EU5 and Japan) markets- Extensive domain knowledge in diagnostics (e.g., engaged in 2 molecular diagnostic project and a biomarker-based wearable diagnostic project) market landscape, regulatory, and market access- Proficient data modeling, analytics, and visualization skills (Excel, Tableau) to support strategic insights- Effective written and verbal communication skills; created and presented both executive-level corporate strategy documents and focused deliverables for product-level teams- Created research materials (e.g., product profiles, discussion guides, screeners, etc.) and performed hundreds of primary research interviews with top-tier key opinion leaders, physicians, payers, and other stakeholders to identify critical project insights

Feb'20 Associate Project Leader -> Sep'20 Project LeaderAssist Fortune 500 and US government clients in searching for and acquiring innovative technology. My role integrates technical knowledge across a wide range of disciplines with strong project management, communication, and presentation skills.Responsibilities include:- Research, vet, and present over 90 innovative technologies to clients in the fields of consumer healthcare, medical devices, biopharma, personal care, etc.- As an account owner, managed a key consumer healthcare client account and accelerated multiple projects which led to an additional contract with 140% increased revenue- Build tailored business cases around promising solution providers with overarching consideration of scientific background, regulatory status, commercial potential, competitive landscape, and intellectual property potential- Facilitate over 10 engagements between clients and solution providers across industries towards partnership including licensing, partnership, and acquisition

- Studied ruthenium drugs for innovative dual photochemotherapy targeting cancer cells apoptosis upon selected red-light irradiation.- Demonstrated the ability of a new dirhodium complex to act as a sensitizer-free photocatalyst (published in Nature Chemistry). Showed 5-folds increased efficiency compared to the next known H2 generation photocatalyst with increased stability and facile synthetic pathway.

- Performed X-ray Transient Absorption (XTA) to investigate the excited state structural change in dirhodium complexes for photochemotherapy applications.